Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
JSPR

JSPR - Jasper Therapeutics, Inc. Stock Price, Fair Value and News

$1.58-0.06 (-3.66%)
Market Closed

Price Targets

JSPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JSPR Price Action

Last 7 days

4.0%

Last 30 days

-10.2%

Last 90 days

-27.5%

Trailing 12 Months

-72.7%

JSPR RSI Chart

JSPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JSPR Valuation

Market Cap

44.2M

Price/Earnings (Trailing)

-0.49

Price/Sales (Trailing)

12.35

EV/EBITDA

0.67

Price/Free Cashflow

-0.58

JSPR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

JSPR Fundamentals

JSPR Revenue

Revenue (TTM)

4.0M

JSPR Earnings

Earnings (TTM)

-91.0M

Earnings Growth (Yr)

-0.53%

Earnings Growth (Qtr)

29.89%

JSPR Profitability

EBT Margin

-86.28%

Return on Equity

-786.63%

Return on Assets

-158.38%

Free Cashflow Yield

-172.85%

JSPR Investor Care

Shares Dilution (1Y)

86.55%

Diluted EPS (TTM)

-5.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.0M000
20230000
20220000
20190000
Get all data in R, Python etc through our Historical Stock Data APIs

About Jasper Therapeutics, Inc.

JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
 CEO
 WEBSITEjaspertherapeutics.com/
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES35

Jasper Therapeutics, Inc. Frequently Asked Questions

JSPR is the stock ticker symbol of Jasper Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Jasper Therapeutics, Inc. is 44.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check JSPR's fair value in chart for subscribers.

The fair value guage provides a quick view whether JSPR is over valued or under valued. Whether Jasper Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Jasper Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JSPR.

As of Wed Jan 28 2026, JSPR's PE ratio (Price to Earnings) is -0.49 and Price to Sales (PS) ratio is 12.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JSPR PE ratio will change depending on the future growth rate expectations of investors.